250122-39-5

Upstream product

• 250122-38-4 (2R,4R)-4-benzyloxypyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 114676-59-4 (2R,4R)-4-hydroxy-2-methoxycarbonylpyrrolidine hydrochloride 
• 23583-21-3 ethyl-3-benzylamino propionate 
• 136024-61-8 (4R)-benzyloxy-(2S)-formylpyrrolidine-1-carboxylic acid tert-butyl ester 
• 109953-95-9 tert-butyl (2S,4R)-4-(benzyloxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 40350-83-2 (2S,4R)-4-(benzyloxy)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid 
• 869527-82-2 tert-butyl (2R,4R)-4-benzyloxy-2-hydroxymethylpyrrolidine-1-carboxylate 
• 2584-71-6 cis-hydroxy-D-proline 
• 114676-47-0 (2R,4R)-4-Hydroxy-pyrrolidine-2-carboxylic acid methyl ester 
• 114676-69-6 (2R,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 869527-83-3 tert-butyl (2R,4R)-4-benzyloxy-2-[(1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-2-nitropropyl]pyrrolidine-1-carboxylate 
• 1221264-26-1 (2R,4R)-tert-butyl 4-(benzyloxy)-2-((1R,2S)-1-hydroxy-2-nitro-3-phenylpropyl)pyrrolidine-1-carboxylate 
• 1221264-23-8 (4R)-tert-butyl 2-((1S,2S)-2-benzyl-1-hydroxy-3-((S)-4-isopropyl-2-oxooxazolidin-3-yl)-3-oxopropyl)-4-(benzyloxy)pyrrolidine-1-carboxylate 
• 1221264-24-9 (2S,3S)-2-benzyl-3-((4R)-4-(benzyloxy)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-3-hydroxypropanoic acid 
• 1221264-25-0 (4R)-tert-butyl 2-((4S,5S)-4-benzyl-2-oxooxazolidin-5-yl)-4-(benzyloxy)pyrrolidine-1-carboxylate 
• 1221264-22-7 (2R,4R)-tert-butyl 2-((1S,2S)-2-amino-1-hydroxy-3-phenylpropyl)-4-(benzyloxy)pyrrolidine-1-carboxylate 
• 1221263-02-0 (2R,4R)-tert-butyl 4-(benzyloxy)-2-((1S,2S)-1-hydroxy-2-(3-((R)-2-(4-methylthiazol-2-yl)pyrrolidine-1-carbonyl)benzamido)-3-phenylpropyl)pyrrolidine-1-carboxylate 
• 1221263-08-6 N-((1R,2S)-1-((2R,4R)-4-(benzyloxy)pyrrolidin-2-yl)-1-hydroxy-3-phenylpropan-2-yl)-3-((R)-2-(4-methylthiazol-2-yl)pyrrolidine-1-carbonyl)benzamide 
• 869527-87-7 tert-butyl (2R,4R)-2-[(4S,5S)-3-acetyl-4-(3,5-difluorobenzyl)-2,2-dimethyloxazolidin-5-yl]-4-hydroxypyrrolidine-1-carboxylate 
• 250122-46-4 4-(benzylamino-methyl)-2-(5-imidazol-1-yl-1H-indol-3-ylmethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 250122-43-1 4-benzyloxy-2-(5-imidazol-1-yl-1H-indol-3-ylmethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 250122-42-0 3-((2S,4R)-4-Benzyloxy-pyrrolidin-2-ylmethyl)-5-imidazol-1-yl-1H-indole 
• 250122-41-9 (2S,4R)-4-Benzyloxy-2-(3-oxo-propyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Optimization of Hydroxyethylamine Transition State Isosteres as Aspartic Protease Inhibitors by Exploiting Conformational Preferences

NMR conformational analysis of a hydroxyethylamine peptide isostere developed as an aspartic protease inhibitor shows that it is a flexible architecture. Cyclization to form pyrrolidines, piperidines, or morpholines results in a preorganization of the who

AGENTS FOR TREATING PAIN AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, treat pain; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

COMPOUNDS CONTAINING FUSED RINGS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.

BACE INHIBITORS

The present invention provides BACE inhibitors of Formula (I): methods for their use and preparation, and intermediates for their preparation.

2,7-Diazabicyclo[3.3.0]octanes as novel h5-HT(1D) receptor agonists

The conformational restriction of a (benzylamino)methyl substituted pyrrolidine to form 2,7-diazabicyclo[3.3.0]octanes has led to a series of compounds with high affinity at the h5-HT(1D) receptor as well as dramatically increased concentrations in the hepatic portal vein following oral administration.